U.S., China Trade Talks Make ‘Substantial Progress,' Bessent Says
U.S. Treasury Secretary Scott Bessent said the U.S. and China made 'substantial progress' in talks to diffuse the trade war between the two countries after President Donald Trump announced tariffs of 145% against China last month, multiple outlets reported Sunday.
Treasury Secretary Scott Bessent testifies before the House Committee on Appropriations, ... More Subcommittee on Financial Services and General Government, oversight hearing of the U.S. Department of the Treasury on Capitol Hill in Washington, Tuesday, May 6, 2025. (AP Photo/Jose Luis Magana)
More details will come Monday, Bessent said after talks concluded in Geneva on Sunday.
Bessent said there was 'a great deal of productivity' in Sunday's talks, according to a clip posted by Trump's rapid response team.
Sunday was the second day representatives—Bessent, U.S. Trade Representative Jamieson Greer, Chinese Vice Premier He Lifeng and two Chinese vice ministers—met to discuss trade policies.
This story is developing and will be updated.
Get Forbes Breaking News Text Alerts: We're launching text message alerts so you'll always know the biggest stories shaping the day's headlines. Text 'Alerts' to (201) 335-0739 or sign up here.
More details from the talks. Bessent said Sunday 'there will be a complete briefing tomorrow morning.'
US, China Made 'Substantial Progress' in Talks in Geneva (Bloomberg)
Trump Floats 80% China Tariffs And 'Many' Other Deals—As U.S. And China Prepare For Trade Talks (Forbes)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
14 minutes ago
- Associated Press
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or about September 13, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 8, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zenas BioPharma, Inc. ('Zenas' or the 'Company') (NASDAQ: ZBIO) and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Zenas' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Zenas BioPharma class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
Associated Press
14 minutes ago
- Associated Press
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action
NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between October 31, 2024 and April 30, 2025, both dates inclusive (the 'Class Period'), of the important July 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Organon securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Organon class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 22, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Organon's priorities, particularly, related to capital allocation through quarterly dividends. Notably, defendants concealed the high priority of Organon's debt reduction strategy following Organon's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Organon class action, go to call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
Fox News
17 minutes ago
- Fox News
National guard deployed by Trump in LA as protesters clash with ICE
All times eastern Maria Bartiromo's Wall Street Maria Bartiromo's Wall Street FOX News Radio Live Channel Coverage
